LNN
Lindsay Corporation
Set alert
- YTD
- -8.69%
- 1 year
- -2.24%
- Open
- 106.40
- Prev close
- 106.38
- Mkt cap
- 1.09B
- Vol
- 176.73K
- Avg vol
- 156.18K
- EPS
- 5.33
- P/E
- 20.19
- Div yield
- 1.43%
More statistics
- Low
- 105.71
- High
- 107.93
- Forward P/E
- 18.79
- Beta
- 0.68
- Short ratio
- 5.36
- Inst. own
- 108.73%
- Dividend
- 1.52
- Ex-div date
- Nov 15, 2026
- Earnings
- Jan 7, 2027
- 50-d avg
- 113.80
- 200-d avg
- 116.94
- 1y target
- 122.00
Discussion (1)
Sign in to join the discussion
VICKY HANUKA LNN 3 years ago #1Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.